Version history

{
  "session_id": "sess_687fb884-6d31-47c3-a83f-074bad980db6_task_66f1207e_recon",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "Domain expert assessment for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation\n\nThe practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.\n\nFor model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.\n\nThe development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis. The risk is that therapeutic tractability may lag mechanistic clarity: even if mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.",
  "tokens_used": "417",
  "persona_id": "persona-domain_expert"
}